A Study of HC006 in Subjects With Advanced Solid Tumors

Summary

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics (PK), Immunogenicity and preliminary antitumor activity of HC006 in subjects with advanced solid tumor malignancies. This study is a first-in-human (FIH) study of HC006 in subjects with advanced solid tumors.

Timeline

Start

2024-02-27

Primary completion

2026-03-15

Completion

2026-07-16

Drugs

Indications